Aprea Therapeutics (NASDAQ: APRE) files updated January 2026 corporate presentation

Rhea-AI Filing Summary

Aprea Therapeutics, Inc. filed a current report to note that it has updated its corporate presentation slide deck as of January 9, 2026. The refreshed investor presentation is included as Exhibit 99.1 and is incorporated by reference, meaning it is treated as part of the official disclosure record. The filing does not describe the specific changes to the presentation, only that a new January 2026 version is now available.

0001781983false00017819832026-01-092026-01-09

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

January 9, 2026

Date of Report (Date of earliest event reported)

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​
Delaware	001-39069	84-2246769
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

​	​
3805 Old Easton Road Doylestown, PA (Address of principal executive offices)	18902 (Zip Code)

​

Registrant’s telephone number, including area code: (215) 948-4119

(Former name or former address, if changed since last report): Not applicable

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

​	​
☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​	Trading Symbol(s)	​ ​	Name of each exchange on which registered
Common stock, par value $0.001 per share	​	APRE	​	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 8.01Other Events.

On January 9, 2026, Aprea Therapeutics, Inc. updated its corporate presentation slide deck. A copy of the corporate presentation slide deck is filed as Exhibit 99.1 hereto and incorporated herein by reference.

​

Item 9.01Financial Statements and Exhibits.

​

(d) Exhibits.

​	​	​
Exhibit Number	​ ​ ​	Description
99.1	​	Corporate Presentation (January 2026).
104	​	Cover Page Interactive Data File (embedded within the inline XBRL document).

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​
​	Aprea Therapeutics, Inc.
​	​
Dated: January 9, 2026	By:	/s/ Oren Gilad
​	Name:	Oren Gilad, Ph.D.
​	Title:	President and Chief Executive Officer

​

​

​

​

FAQ

What did Aprea Therapeutics (APRE) disclose in this Form 8-K?

Aprea Therapeutics reported that on January 9, 2026 it updated its corporate presentation slide deck and filed the updated January 2026 presentation as an exhibit.

Which exhibit in the Aprea Therapeutics (APRE) 8-K contains the new presentation?

The updated corporate presentation is filed as Exhibit 99.1 and is described as “Corporate Presentation (January 2026).”

Does this Aprea Therapeutics (APRE) 8-K announce any new financial results?

No. This report only states that the company has updated and filed its corporate presentation; it does not provide financial results or earnings data.

Why is Aprea Therapeutics (APRE) filing an 8-K for a corporate presentation update?

By filing the January 2026 corporate presentation as an exhibit and incorporating it by reference, the company makes the updated investor materials part of its official SEC disclosure record.

Who signed this Aprea Therapeutics (APRE) Form 8-K?

The report was signed on behalf of Aprea Therapeutics, Inc. by Oren Gilad, Ph.D., the company’s President and Chief Executive Officer.